• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of Methyl 2-bromo-5-methylnicotinate (CAS: 136227-39-9) in Chemical Biology and Pharmaceutical Research

Methyl 2-bromo-5-methylnicotinate (CAS: 136227-39-9) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of pharmaceuticals targeting neurological and inflammatory diseases. Recent studies have highlighted its versatility as a building block in medicinal chemistry, enabling the construction of complex molecular architectures with potential therapeutic applications. This research brief synthesizes the latest findings on the compound's applications, synthetic methodologies, and biological evaluations.

In the context of synthetic chemistry, Methyl 2-bromo-5-methylnicotinate has been employed in palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, to generate diverse nicotinic acid derivatives. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of novel kinase inhibitors, where the bromo-substituent facilitated efficient functionalization at the C2 position. The study reported a 78% yield in the coupling reaction with aryl boronic acids, underscoring the compound's reactivity and synthetic value.

From a biological perspective, derivatives synthesized from Methyl 2-bromo-5-methylnicotinate have shown promising activity against neurodegenerative targets. Research from the University of Cambridge (2024) revealed that certain analogs exhibited potent inhibition of acetylcholinesterase (AChE), with IC50 values in the nanomolar range. These findings suggest potential applications in Alzheimer's disease therapy, although further in vivo studies are required to assess pharmacokinetic properties and blood-brain barrier penetration.

The compound has also gained attention in the development of anti-inflammatory agents. A recent patent application (WO2023124567) disclosed a series of 5-methylnicotinate derivatives that demonstrated significant suppression of TNF-α production in macrophage cells. The lead compound from this series, derived from Methyl 2-bromo-5-methylnicotinate, showed 85% inhibition at 10 μM concentration without apparent cytotoxicity, making it a promising candidate for rheumatoid arthritis treatment.

Quality control and analytical methods for Methyl 2-bromo-5-methylnicotinate have seen advancements as well. A 2024 publication in Analytical Chemistry presented a novel HPLC-MS method for quantifying trace impurities in commercial batches of the compound. The method achieved a detection limit of 0.01% for related substances, addressing previous challenges in purity assessment that were critical for pharmaceutical applications.

Looking forward, the research community anticipates expanded applications of Methyl 2-bromo-5-methylnicotinate in PROTAC (Proteolysis Targeting Chimera) development, leveraging its bromo-substituent for linker attachment. Preliminary results from Merck & Co. (2024) indicate successful incorporation of the compound into BRD4-targeting PROTACs, although optimization of degradation efficiency remains ongoing. These developments position 136227-39-9 as a structurally valuable scaffold in modern drug discovery paradigms.

• 26218-78-0(methyl 6-bromopyridine-3-carboxylate)
• 55304-85-3(2,6-dibromopyridine-3-carboxylic acid)
• 168629-64-9(tert-butyl 2-bromopyridine-3-carboxylate)
• 53087-78-8(ethyl 2-bromopyridine-3-carboxylate)
• 65996-16-9(Ethyl 2-bromo-5-methylnicotinate)
• 78686-82-5(methyl 2,5-dibromopyridine-3-carboxylate)
• 35905-85-2(2-bromopyridine-3-carboxylic acid)
• 52718-95-3(methyl 2-bromopyridine-3-carboxylate)
• 65996-06-7(2-Bromo-5-methylnicotinic acid)
• 1210451-92-5(Methyl 6-bromo-5-methylnicotinate)